The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | What will define a “good outcome” in R/R MM in the next five years?
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses factors he believes will have the biggest impact on how we define a ‘good outcome’ in relapsed/refractory multiple myeloma (R/R MM) in the next 5 years, highlighting the need to incorporate CAR-T into frontline treatment and prioritize treatment-free intervals, quality of life, and patient-derived decisions. Dr Ocio also emphasizes the importance of individualized treatment approaches, such as MRD-guided or risk-guided decisions, to optimize outcomes and minimize adverse events. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So now that we have so many good options, they are being approved more and more, we have great options at the diagnosis with, you know, 10 to 15 years progression-free survival. This is great. Also, at relapse, we also have several other options for rescuing these patients. What do we need now that we have such good options? And this is how I see the field evolving in five years...
So now that we have so many good options, they are being approved more and more, we have great options at the diagnosis with, you know, 10 to 15 years progression-free survival. This is great. Also, at relapse, we also have several other options for rescuing these patients. What do we need now that we have such good options? And this is how I see the field evolving in five years. One is the incorporation of CAR-Ts. We already have them at three labs, but going to the front line, how CAR-Ts can impact the treatment of myeloma frontline. This also leads to another very important point for me, which is a treatment-free interval. So now that we have these good outcomes, which patients require less treatment than the one we are giving? So it’s very important for some patients to stop treatment because they consider they are out of treatment. As I used to say, sometimes some patients may think, okay, I’m having treatment in maintenance as I’m having an antihypertensive drug, but for others, it is really that they are having an antineoplastic drug, so this is also different, and we have to consider what is the patient preference or the patient’s idea, but having treatment limited is very, very important. And the third point for me is the quality of life, also the safety, the convenience, reducing the visits to the hospital, this is also very important, and also in terms of tolerability, to have a very good quality of life in terms of adverse events, the taste, the keratopathy, the peripheral neuropathy, all these that we think is very, very important. And finally, another important point for me in the future is to make patient-derived decisions, MRD-guided or risk-guided or whatever. So, in this time, we don’t have to go with the same treatment for everybody. We can start with that, but then decide based on the response, for instance, you have to switch to another one, or we can stop some treatment because they are in a very good response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
